BMRN (BioMarin Pharmaceutical) Interest Expense : $-12 Mil (TTM As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is BioMarin Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioMarin Pharmaceutical's interest expense for the three months ended in Mar. 2025 was $ -3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioMarin Pharmaceutical's Operating Income for the three months ended in Mar. 2025 was $ 224 Mil. BioMarin Pharmaceutical's Interest Expense for the three months ended in Mar. 2025 was $ -3 Mil. BioMarin Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2025 was 78.21. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioMarin Pharmaceutical Interest Expense Historical Data

The historical data trend for BioMarin Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMarin Pharmaceutical Interest Expense Chart

BioMarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-27.48

-14.74

-13.81

-13.82

-12.34

BioMarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-3.55	-3.57	-2.97	-2.25	-2.86

BioMarin Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12 Mil.

BioMarin Pharmaceutical (NAS:BMRN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioMarin Pharmaceutical's Interest Expense for the three months ended in Mar. 2025 was $-3 Mil. Its Operating Income for the three months ended in Mar. 2025 was $224 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $596 Mil.

BioMarin Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	223.909	/	-2.863
	=	78.21

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. BioMarin Pharmaceutical Inc has enough cash to cover all of its debt. Its financial situation is stable.

BioMarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioMarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Executives

Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller	officer: EVP, Chief Financial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
George Eric Davis	officer: VP, General Counsel	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jean Jacques Bienaime	director, officer: Chief Executive Officer	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Robert Ajer	officer: EVP, Chief Commercial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs	officer: Chief Medical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
V Bryan Lawlis	director
Richard A Meier	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612